Evaluation of response to multikinase inhibitor in metastatic renal cell ... - UroToday PDF Print
UroToday
Multikinase inhibitor (MKI) is a promising drug for treatment of metastatic renal cell carcinoma (mRCC). We explained the usefulness of

...

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.